Insulin Pens Market to Reflect a Holistic Expansion During 2019-2027

According to a new market research study titled 'Insulin Pens Market - Global Analysis and Forecasts by Product Type, Application and Distribution Channel', the global insulin pens market is expected to reach US$ 8,286.6 Mn in 2027 from US$ 3,957.0 in 2018. The market is estimated to grow with a CAGR of 8.8% from 2019-2027. The report highlights the trends prevalent in the global insulin pens market and the factors driving the market along with those that act as deterrents to its growth.

Get a Sample Study Report

The insulin pens market on the basis of product type is segmented in to disposable and reusable. In 2018, the disposable segment held the largest market share of 62.6% of the insulin pens market, by product type. The disposable insulin pens segment is expected to dominate its market share in 2018 owing to the advantages offered by these type that include ease of use, low cost, less threat of needle-stick infection and others. The similar segment is also anticipated to witness the fastest growth rate of 9.0% during the forecast period, 2019 to 2027 owing to its rising usage as pre-filled cartridges in the newly launched insulin dosages by leading pharmaceutical manufacturers.

The key factors that are driving the growth of the market are rising incidence of diabetes, growing geriatric population, and increasing adoption of insulin pens over conventional vials and syringes. However, the factors restraining the market growth are the high cost of insulin pens and the availability of alternatives to insulin pens in the market. On the other hand, the high potential of market growth in the emerging economies is one of the growth opportunities for market players. In recent years, there has been considerable development in the field of medical drug delivery devices. Insulin administration is a common procedure in the diabetic population. Traditional insulin syringes have several disadvantages that include the experience of pain by patients due to repeated pricks, discomfort in carrying both insulin bottle as well as syringe, risk of needle re-use associated infections and needle-stick injuries as well as difficulty in delivering a mixture of two or more liquids together in one syringe. Additionally, self-administration of insulin through syringes and vials is time-taking and difficult that has reduced the adoption of conventional insulin injection methods over the past years and led to increased adoption of injection pens.

Some of the prominent players operating in insulin pens market are, Novo Nordisk A/S, Owen Mumford, Sanofi, Ypsomed AG, Biocon, Companion Medical, BERLIN CHEMIE AG, Eli Lilly and Company, pendiq, and Emperra GmbH E-Health Technologies among others. The market players are focused on bringing new and innovative products and services to sustain their position in the market. For instance, in June 2016, Haselmeier announced the German launch of the BerliPen areo 3 through BERLIN CHEMIE AG. Key features of this third-generation BerliPen are an optimized dose indicator, the innovative low-friction mechanism for smooth injection release in addition to an enhanced feeling of safety utilizing audible and tactile dose settings.